Literature DB >> 29132568

Molecular Subtypes and Local-Regional Control of Breast Cancer.

Simona Maria Fragomeni1, Andrew Sciallis2, Jacqueline S Jeruss3.   

Abstract

In the era of personalized medicine, there has been significant progress regarding the molecular analysis of breast cancer subtypes. Research efforts have focused on how classification of subtypes could provide information on prognosis and influence treatment planning. Although much is known about the impact of different molecular subtypes on disease-specific survival, more recent studies have investigated the role of the different molecular subtypes on local-regional recurrence. This is an area of active study, and in recent years there has been significant progress. This article describes outcomes among disease subtypes to aid in optimal surgical decision-making to improve local-regional control.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Gene signatures; Immunohistochemical surrogates; Local-regional recurrence; Molecular subtypes

Mesh：

Substances：

Year:  2018        PMID： 29132568      PMCID： PMC5715810          DOI： 10.1016/j.soc.2017.08.005

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  156 in total

1.  Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Authors:  Maggie C U Cheang; Miguel Martin; Torsten O Nielsen; Aleix Prat; David Voduc; Alvaro Rodriguez-Lescure; Amparo Ruiz; Stephen Chia; Lois Shepherd; Manuel Ruiz-Borrego; Lourdes Calvo; Emilio Alba; Eva Carrasco; Rosalia Caballero; Dongsheng Tu; Kathleen I Pritchard; Mark N Levine; Vivien H Bramwell; Joel Parker; Philip S Bernard; Matthew J Ellis; Charles M Perou; Angelo Di Leo; Lisa A Carey
Journal:  Oncologist       Date:  2015-04-23

2.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

3.  Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.

Authors:  M Overgaard; M B Jensen; J Overgaard; P S Hansen; C Rose; M Andersson; C Kamby; M Kjaer; C C Gadeberg; B B Rasmussen; M Blichert-Toft; H T Mouridsen
Journal:  Lancet       Date:  1999-05-15       Impact factor: 79.321

4.  Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial.

Authors:  Erik van Werkhoven; Guus Hart; Harm van Tinteren; Paula Elkhuizen; Laurence Collette; Philip Poortmans; Harry Bartelink
Journal:  Radiother Oncol       Date:  2011-08-05       Impact factor: 6.280

5.  Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival.

Authors:  P H Elkhuizen; M J van de Vijver; J Hermans; H M Zonderland; C J van de Velde; J W Leer
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-03-01       Impact factor: 7.038

6.  Risk of locoregional recurrence by receptor status in breast cancer patients receiving modern systemic therapy and post-mastectomy radiation.

Authors:  J E Panoff; J Hurley; C Takita; I M Reis; W Zhao; V Sujoy; C R Gomez; M Jorda; L Koniaris; J L Wright
Journal:  Breast Cancer Res Treat       Date:  2011-04-08       Impact factor: 4.872

7.  Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation study.

Authors:  Syed K Mohsin; Heidi Weiss; Thomas Havighurst; Gary M Clark; Melora Berardo; Le D Roanh; Ta V To; Zhang Qian; Zho Qian; Richard R Love; D Craig Allred
Journal:  Mod Pathol       Date:  2004-12       Impact factor: 7.842

8.  Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma.

Authors:  Gavin C Harris; Helen E Denley; Sarah E Pinder; Andrew H S Lee; Ian O Ellis; Christopher W Elston; Andrew Evans
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

Review 9.  Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis.

Authors:  Francisco E Vera-Badillo; Arnoud J Templeton; Paulo de Gouveia; Ivan Diaz-Padilla; Philippe L Bedard; Mustafa Al-Mubarak; Bostjan Seruga; Ian F Tannock; Alberto Ocana; Eitan Amir
Journal:  J Natl Cancer Inst       Date:  2013-11-22       Impact factor: 13.506

10.  Post-mastectomy radiotherapy benefits subgroups of breast cancer patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.

Authors:  Yu-Li Su; Shan-Hsuan Li; Yen-Yang Chen; Hui-Chun Chen; Yen Tang; Cheng-Hua Huang; Fong-Fu Chou; Shih-Chung Wu; Kun-Ming Rau
Journal:  Radiol Oncol       Date:  2014-07-10       Impact factor: 2.991
View more
  104 in total

1.  Gas6 expression is reduced in advanced breast cancers.

Authors:  Ayman M Ibrahim; Zane Gray; Angelica M Gomes; Leann Myers; Fariba Behbod; Heather L Machado
Journal:  NPJ Precis Oncol       Date:  2020-04-24

2.  miR-31-5p may enhance the efficacy of chemotherapy with Taxol and cisplatin in TNBC.

Authors:  Xiaowei Shen; Jiaqi Lei; Lei Du
Journal:  Exp Ther Med       Date:  2019-11-12       Impact factor: 2.447

Review 3.  Non-Coding RNAs as Regulators and Markers for Targeting of Breast Cancer and Cancer Stem Cells.

Authors:  Kirti S Prabhu; Afsheen Raza; Thasni Karedath; Syed Shadab Raza; Hamna Fathima; Eiman I Ahmed; Shilpa Kuttikrishnan; Lubna Therachiyil; Michal Kulinski; Said Dermime; Kulsoom Junejo; Martin Steinhoff; Shahab Uddin
Journal:  Cancers (Basel)       Date:  2020-02-04       Impact factor: 6.639

4.  Recombinant anthrax lethal toxin inhibits cell motility and invasion in breast cancer cells through the dysregulation of Rho GTPases.

Authors:  Dana El-Chami; Maria Al Haddad; Ralph Abi-Habib; Mirvat El-Sibai
Journal:  Oncol Lett       Date:  2020-12-31       Impact factor: 2.967

Review 5.  Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer.

Authors:  Jun-Cheng Xuhong; Xiao-Wei Qi; Yi Zhang; Jun Jiang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 6.  Comprehensive comparison of theranostic nanoparticles in breast cancer.

Authors:  Amin Nikdouz; Nima Namarvari; Ramin Ghasemi Shayan; Arezoo Hosseini
Journal:  Am J Clin Exp Immunol       Date:  2022-02-15

7.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastasis from breast cancer: a preliminary report of 4 cases.

Authors:  Jun-Hui Yu; Yu Feng; Xin-Bao Li; Cheng-Yan Zhang; Feng Shi; Song-Lin An; Gang Liu; Yan-Bin Zhang; Kai Zhang; Zhong-He Ji; Bing Li; Guo-Jun Yan; Yan-Ping Li; Yan Li
Journal:  Gland Surg       Date:  2021-04

8.  Integration of Multitargeted Polymer-Based Contrast Agents with Photoacoustic Computed Tomography: An Imaging Technique to Visualize Breast Cancer Intratumor Heterogeneity.

Authors:  Lei Li; Deepanjali Patil; Greg Petruncio; Kathleen K Harnden; Jisha V Somasekharan; Mikell Paige; Lihong V Wang; Carolina Salvador-Morales
Journal:  ACS Nano       Date:  2021-01-19       Impact factor: 15.881

9.  Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.

Authors:  Nina Oparina; Malin C Erlandsson; Anna Fäldt Beding; Toshima Parris; Khalil Helou; Per Karlsson; Zakaria Einbeigi; Maria I Bokarewa
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639

Review 10.  Natural Killer Cell Dysfunction in Obese Patients with Breast Cancer: A Review of a Triad and Its Implications.

Authors:  Esraa Elaraby; Abdullah Imadeddin Malek; Hanan W Abdullah; Noha Mousaad Elemam; Maha Saber-Ayad; Iman M Talaat
Journal:  J Immunol Res       Date:  2021-06-07       Impact factor: 4.818
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.